HELP INCREASE VACCINE UPTAKE

Offering a nasal spray option may increase flu vaccine uptake among your patients1

Offering a nasal spray option may increase flu vaccine uptake among your patients1

Sample Patients Image
 

Based on a recent survey, when both a nasal spray and an injectable option were made available for flu vaccination:1

Nasal Spray Flu Vaccine StatisticsNasal Spray Flu Vaccine Statistics Nasal Spray Flu Vaccine Statistics

which is an increase nationally of
~2.3 million children and ~4.9 million adults


Increase in vaccination with a nasal spray option was approximated by lpsos' KnowledgePanel®, which was supported by AstraZeneca:1

  • The largest and most well-established probability-based online polling panel in the US
  • 2021 poll based on nationally representative probability sample: 2,041 adults 18-49 years of age; 4,672 parents of children 2-17 years of age
  • Statistically valid representation of the total US population, including traditionally harder-to-reach groups, such as Black, Latino, and Asian groups, and households without internet
  • Likelihood was determined based on the Clancy-scale calibrated response among unvaccinated people (mean)

IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of the potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUMIST
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information for FLUMIST, including Patient Information.

You may report side effects related to AstraZeneca products.